- |||||||||| oremepermin alfa (KP-100) / Kringle
Trial completion date, Trial primary completion date: Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury (clinicaltrials.gov) - Aug 23, 2022
P3, N=25, Recruiting,
Trial primary completion date: Mar 2023 --> Dec 2022 Trial completion date: Sep 2022 --> Jun 2023 | Trial primary completion date: Sep 2020 --> Mar 2023
- |||||||||| KP-100IT / Kringle
Preclinical, Journal: Hepatoprotective Activity of InlB321/15, the HGFR Ligand of Bacterial Origin, in CCI4-Induced Acute Liver Injury Mice. (Pubmed Central) - Apr 15, 2019
Both InlB321/15 and rhHGF improved macroscopic liver parameters (liver mass was 1.51, 1.27 and 1.15 g for the vehicle, InlB321/15 and rhHGF, respectively, p < 0.05), reduced necrosis (24.0%, 16.18% and 21.66% of the total area for the vehicle, InlB321/15 and rhHGF, respectively, p < 0.05). Obtained data suggest that InlB321/15 is a promising candidate for a tissue repair agent.
- |||||||||| oremepermin alfa (KP-100) / Kringle
Trial completion, Trial completion date, Trial primary completion date: Phase I/II Study of KP-100IT in Acute Spinal Cord Injury (clinicaltrials.gov) - Feb 21, 2019
P1/2, N=45, Completed,
Obtained data suggest that InlB321/15 is a promising candidate for a tissue repair agent. Recruiting --> Completed | Trial completion date: Oct 2018 --> Jul 2018 | Trial primary completion date: Mar 2018 --> Dec 2017
- |||||||||| oremepermin alfa (KP-100) / Kringle
Trial primary completion date: Phase I/II Study of KP-100IT in Acute Spinal Cord Injury (clinicaltrials.gov) - Oct 11, 2016
P1/2, N=48, Recruiting,
Recruiting --> Completed | Trial completion date: Oct 2018 --> Jul 2018 | Trial primary completion date: Mar 2018 --> Dec 2017 Trial primary completion date: Nov 2016 --> Mar 2018
|
